Skip to main content
. Author manuscript; available in PMC: 2025 Jul 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2024 Jul 1;96(3):259–269. doi: 10.1097/QAI.0000000000003440

Table 4:

Male Participant Outcomes

Variable Level Estimate (95% CI) P-value
Study group Intervention 0.088 (0.017, 0.158) 0.015
Age at enrollment (years) 0.004 (0.002, 0.007) 0.001
Education None −0.038 (−0.110, 0.035) 0.31
Some-completed primary −0.014 (−0.054, 0.026) 0.49
Marital status Single 0.004 (−0.054, 0.062) 0.90
Common law/live together 0.081 (0.026, 0.135) 0.004
ART Regimen (at enrollment) DTG 0.187 (0.143, 0.232) <0.001
Employment status Agriculture/Domestic 0.011 (−0.030, 0.051) 0.61
Depression score −0.002 (−0.006, 0.002) 0.42
HIV Knowledge score 0.006 (0.001, 0.010) 0.012
HIV Stigma score 0.001 (−0.001, 0.002) 0.54

Reference levels: Study group (control); Education (some secondary or beyond); Marital status (married); ART regimen (other); Employment status (other).

ART = Antiretroviral therapy; DTG = Dolutegravir.